Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could stopping acid reflux drugs improve IBD treatment?

NCT ID NCT07691138

Disease control Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study explores whether people with inactive inflammatory bowel disease (IBD) can safely stop taking proton pump inhibitors (PPIs), a common acid-reducing medication. Evidence suggests PPIs may make IBD treatments less effective and increase hospital visits. The trial will recruit 80 participants aged 16 and older with stable IBD who have been on PPIs for over six months, randomly assigning half to stop the medication. Researchers will measure how many can successfully stop, how well they adhere, and whether IBD symptoms change over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Proton pump inhibitor (PPI) withdrawal
What this could lead to
If successful, this could show that stopping PPIs is safe and may improve how well IBD medications work, reducing the need for hospital care.
What could go wrong
This is a small feasibility study, not a large trial. Some people may experience a short-term increase in acid reflux after stopping PPIs, and it is unclear how many can stay off them long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 16 years or older. * An IBD diagnosis as defined through SNOMED codes in primary care databases \[Appendix 5\] * Taking a PPI regularly for \>6 months prior to enrolment * Patient-confirmed compliance with PPI therapy (\>75% of prescribed doses) * Able to give full, independent valid Informed consent * Stable disease as defined by no change in medication or IBD-related surgery for the last 3 months. Exclusion Criteria: * Unable to participate fully in all aspects of the clinical trial. * Barrett's oesophagus * Peptic disease at a recent upper GI endoscopy * Zollinger-Ellison Syndrome * Eosinophilic oesophagitis * Chronic NSAID usage * Pulmonary fibrosis. * Declined consent to data sharing * History of dementia * Terminal illness * Present malignancy * Active history of mental illness * In a care home * Alcohol misuse * Illicit drug misuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn's disease Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Nottingham

    RECRUITING

    Nottingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.